NEW YORK, Nov. 19, 2018 /PRNewswire/ -- Actinium
Pharmaceuticals, Inc. (NYSE American: ATNM) announced
today that management will present at the 30th Annual
Piper Jaffray Healthcare conference that is being held at the Lotte
New York Palace hotel, November
26-29. The live webcast of the presentation will be
available on Actinium's investor relations webpage at:
https://ir.actiniumpharma.com/presentations-webinars or by clicking
on the following link:
https://event.webcasts.com/starthere.jsp?ei=1221814&tp_key=f710d7f814.
Details of Actinium's presentation are as follows:
Date: Tuesday, November 27,
2018
Time: 2:10 PM ET
Location: Harlem Track – Kennedy 2, 4th Floor
Venue: Lotte New York Palace
Conference attendees may schedule a meeting with Actinium's
management by contacting Steve
O'Loughlin, Actinium's Principal Financial Officer,
soloughlin@actiniumpharma.com.
About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals Inc. is focused on improving patient
access and outcomes to cellular therapies such as bone marrow
transplant (BMT) and CAR-T with its proprietary, chemotherapy free
or sparing, targeted conditioning technology. Actinium is the only
company with a multi-disease, multi-target, drug development
pipeline focused on targeted conditioning. Its targeted
conditioning technology is enabled by ARC's or Antibody Radiation
Conjugates that combine the targeting ability of monoclonal
antibodies with the cell killing ability of radioisotopes.
Actinium's pipeline of clinical-stage targeted conditioning ARCs
target the antigens CD45 and CD33 for patients with a broad range
of hematologic malignancies including acute myeloid leukemia (AML),
myelodysplastic syndrome (MDS) and multiple myeloma (MM), acute
lymphoblastic leukemia (ALL), Hodgkin's lymphoma and Non-Hodgkin's
lymphoma. Actinium's Iomab-ACT program is designed to be a
universal lymphodepletion technology intended to eliminate the need
for chemotherapy-based conditioning prior to CAR-T or other
adoptive cellular therapies.
Iomab-B, Actinium's lead targeted conditioning product
candidate, is currently enrolling patients in the pivotal Phase 3
SIERRA trial in patients age 55 or older, with active, relapsed or
refractory AML. Iodine-131-apamistamab (Iomab-B), combines the
anti-CD45 monoclonal antibody labeled with iodine-131 for
myeloablation prior to a bone marrow transplant. CD45 is expressed
on leukemia, lymphoma and normal immune cells. Iomab-B has been
studied in over 500 patients in 10 clinical trials in numerous
hematologic diseases. Actinium's Iomab-ACT program is an expansion
of its CD45 program that is intended to be a universal,
chemotherapy-free solution for targeted lymphodepletion prior to
CAR-T. Through targeted lymphodepletion, the Iomab-ACT program is
expected to improve CAR-T cell expansion, reduce CAR-T related
toxicities and expand patient access to CAR-T treatment and
potentially other adoptive cell therapies. Due to its lower payload
dose, lymphodepletion with the Iomab-ACT program can be
accomplished through a single outpatient infusion. Actinium intends
to advance its Iomab-ACT program with CAR-T focused collaborators
from academia and industry.
Actinium's pipeline also includes a potentially best-in-class
CD33 program with its ARC comprised of the anti-CD33 antibody
lintuzumab labeled with the alpha-particle emitter actinium-225.
Its CD33 program is currently being studied in multiple clinical
trials for targeting conditioning and as a therapeutic in multiple
diseases and indications including AML, MDS and MM. Actinium
applies its CD33 program at high doses to target CD33+ cells of the
myeloid lineage in combination with reduced intensity conditioning
(RIC), which together are intended to result in myeloablative
outcomes with a more benign and well tolerated profile than high
intensity chemotherapy myeloablation. Actinium is focused on
applying its CD33 program at low doses in combination with other
therapeutic modalities including chemotherapy, targeted agents and
immunotherapies.
Actinium is also developing its proprietary AWE or Antibody
Warhead Enabling technology platform which utilizes radioisotopes
including iodine-131 and the highly differentiated actinium-225
coupled with antibodies to target a variety of antigens that are
expressed in hematological and solid tumor cancers. The AWE
technology enables Actinium's internal pipeline and with the
radioisotope Actinium-225 is being utilized in a collaborative
research partnership with Astellas Pharma, Inc. Actinium's clinical
programs and AWE technology platform are covered by a portfolio of
75 patents covering composition of matter, formulations, methods of
use and also methods of manufacturing the radioisotope Actinium-225
in a cyclotron.
More information is available at www.actiniumpharma.com and our
Twitter feed @ActiniumPharma, www.twitter.com/actiniumpharma.
More information is available at www.actiniumpharma.com and the
company's Twitter feed @ActiniumPharma,
www.twitter.com/actiniumpharma.
Contact:
Actinium Pharmaceuticals, Inc.
Steve O'Loughlin
Principal Financial Officer
soloughlin@actiniumpharma.com
Investor Relations
Rx Communications Group
Paula Schwartz
917-322-2216
pschwartz@rxir.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/actinium-pharmaceuticals-inc-to-present-at-30th-annual-piper-jaffray-healthcare-conference-300752652.html
SOURCE Actinium Pharmaceuticals, Inc.